Correlation Between Genmab A/S and Gemina Laboratories

Can any of the company-specific risk be diversified away by investing in both Genmab A/S and Gemina Laboratories at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genmab A/S and Gemina Laboratories into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Genmab AS and Gemina Laboratories, you can compare the effects of market volatilities on Genmab A/S and Gemina Laboratories and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genmab A/S with a short position of Gemina Laboratories. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genmab A/S and Gemina Laboratories.

Diversification Opportunities for Genmab A/S and Gemina Laboratories

0.11

Correlation Coefficient

Genmab A/S  Gemina Laboratories

Average diversification

The 3 months correlation between Genmab and Gemina is 0.11. Overlapping area represents the amount of risk that can be diversified away by holding Genmab AS and Gemina Laboratories in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gemina Laboratories and Genmab A/S is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genmab AS are associated (or correlated) with Gemina Laboratories. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gemina Laboratories has no effect on the direction of Genmab A/S i.e., Genmab A/S and Gemina Laboratories go up and down completely randomly.

Pair Corralation between Genmab A/S and Gemina Laboratories

Assuming the 90 days horizon Genmab AS is expected to under-perform the Gemina Laboratories. But the pink sheet apears to be less risky and, when comparing its historical volatility, Genmab AS is 1.91 times less risky than Gemina Laboratories. The pink sheet trades about -0.02 of its potential returns per unit of risk. The Gemina Laboratories is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  55.00  in Gemina Laboratories on December 29, 2024 and sell it today you would earn a total of  30.00  from holding Gemina Laboratories or generate 54.55% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Genmab AS  vs.  Gemina Laboratories

Genmab A/S

Risk-Adjusted Performance

Very Weak

Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Genmab A/S is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.

Gemina Laboratories

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Gemina Laboratories are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating fundamental drivers, Gemina Laboratories reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Genmab A/S and Gemina Laboratories

The main advantage of trading using opposite Genmab A/S and Gemina Laboratories positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genmab A/S position performs unexpectedly, Gemina Laboratories can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gemina Laboratories will offset losses from the drop in Gemina Laboratories' long position.

The idea behind Genmab AS and Gemina Laboratories pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.